

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY'S DOCKET: YAYON11

In re Application of:	)	Art Unit: 1644
	)	
YAYON et al.	)	Examiner: R. Schwadron, Ph.D.
	)	
Serial No.: 10/561,396	)	Washington, D.C.
	)	
I.A. Filed: June 17, 2004	)	May 12, 2009
	)	
For: TREATMENT OF T CELL...	)	
	)	Confirmation No.: 6136

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID  
SEQUENCE DISCLOSURES

Honorable Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window  
Randolph Building, Mail Stop **Sequence**  
401 Dulany Street  
Alexandria, VA 22314

Sir:

In response to the Notice to Comply of April 15 2009,  
please amend as follows:

**Amendments to the Sequence Listing** begin on page 2 of this paper.

**Remarks/Arguments** begin on page 3 of this paper.

**Attachment:** A copy of the Sequence Listing in ".txt form" is  
being submitted herewith.

Appln. No. 10/561,396  
Amd. dated May 12, 2009  
Reply to Notice to Comply of April 15, 2009

**IN THE SEQUENCE LISTING**

Please substitute the attached Sequence Listing section  
for the last filed Sequence Listing.

REMARKS

Applicants have added into the present specification a substitute paper copy Sequence Listing section according to 37 C.F.R. §1.821(c). Furthermore, attached hereto is a file (either on a 3½" disk or in an online text file) containing the "Sequence Listing" in computer readable form in accordance with 37 C.F.R. §1.821(e).

The following statement is provided to meet the requirements of 37 C.F.R. §1.825(a) and 1.825(b).

I hereby state, in accordance with 37 C.F.R. §1.825(a), that the amendments included in the substitute sheets of the sequence listing are believed to be supported in the application as filed and that the substitute sheets of the sequence listing are not believed to include new matter.

I hereby further state, in accordance with 37 C.F.R. §1.825(b), that the attached copy of the computer readable form is the same as the attached substitute paper copy of the sequence listing.

Under U.S. rules, each sequence must be classified in <213> as an "Artificial Sequence", a sequence of "Unknown" origin, or a sequence originating in a particular organism, identified by its scientific name.

Neither the rules nor the MPEP clarify the nature of the relationship which must exist between a listed sequence and an organism for that organism to be identified as the origin of the sequence under <213>.

Hence, counsel may choose to identify a listed sequence as associated with a particular organism even though that sequence does not occur in nature by itself in that organism (it may be, e.g., an epitopic fragment of a naturally occurring protein, or a cDNA of a naturally occurring mRNA, or even a substitution mutant of a naturally occurring sequence). Hence, the identification of an organism in <213> should not be construed as an admission that the sequence *per se* occurs in nature in said organism.

Similarly, designation of a sequence as "artificial" should not be construed as a representation that the sequence has no association with any organism. For example, a primer or probe may be designated as "artificial" even though it is necessarily complementary to some target sequence, which may occur in nature. Or an "artificial" sequence may be a substitution mutant of a natural sequence, or a chimera of two or more natural sequences, or a cDNA (i.e., intron-free sequence) corresponding to an intron-containing gene, or otherwise a fragment of a natural sequence.

The Examiner should be able to judge the relationship of the enumerated sequences to natural sequences by giving full consideration to the specification, the art cited therein, any further art cited in an IDS, and the results of his or her

Appln. No. 10/561,396  
Amd. dated May 12, 2009  
Reply to Notice to Comply of April 15, 2009

sequence search against a database containing known natural sequences.


Applicants submit that the present application contains patentable subject matter and therefore urge the examiner to pass the case to issuance.

If the examiner has any questions or comments concerning the sequence listing in the above described application, the examiner is urged to contact the undersigned at the phone number below.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant(s)

By

  
Sheridan Neimark  
Registration No. 20,520

SN:pp  
Telephone No.: (202) 628-5197  
Facsimile No.: (202) 737-3528  
G:\BN\W\Webb\Yayon11\pto\2009-05-12SequenceResponse.doc